On March 3rd, 2023, Baheal Pharma Group signed a strategic cooperation agreement with the Changping District government to accelerate the construction of the innovative in vitro diagnostic reagent research and development and production platform under Baheal Pharma Group.
On February 26th, 2023, Baheal Medical announced that it had recently signed a strategic cooperation agreement with Novartis China. The two parties will engage in an in-depth cooperation related to the commercial operation of Novartis' targeted therapy drug Votrient® (Pazopanib Tablets) for the first-line treatment of advanced renal cell carcinoma in the Chinese market.
Osmotic Pump Metformin Hydrochloride Sustained-Release Tablets ® has been successfully included in the National Reimbursement Drug List, which will greatly improve the accessibility and affordability of high-quality hypoglycemic drugs and benefit more diabetic patients.
On November 26, 2022, the donation signing ceremony of "Peking University Baheal Medical Science and Technology Innovation and Achievement Transformation Fund" was held at Peking University Health Science Center.
